Arra::yes::arra early therapeutics development with phase II emphasis

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200622008C
Awardee
Awarding agency
Obligated
$3,953,085

Award facts

Opportunity
  • N01CM5701816 Solicitation number
Contract value 25% obligated
  • $12,405,967.00 Current, with exercised options
  • $15,602,467.00 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition · 11 offers Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Tampa, FL 33612, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Change Order 18 -$57,537
Change Order 17 -$322,496
Other Administrative Action 16 · To extend the arra portion of this contract through 12/31/2013 $0
Other Administrative Action 15 · Other functions the purpose of this modification is to extend the arra portion of this contract through june 30, 2013. $0
Other Administrative Action 14 · The purpose of this modification is to extend the arra portion of this contract through june 30, 2013. $0
Funding Only Action 13 $198,183
Funding Only Action 12 $147,039
Funding Only Action 11 $294,078
Other Administrative Action 10 $0
Funding Only Action 9 $1,132,711
Exercise an Option 8 $115,203
Funding Only Action 7 · Biomedical (basic) $91,738
Funding Only Action 6 · Recovery act - actnow clinical trial 8461 under "early therapeutics development with phase II emphasis" arra::yes::arra $1,206,941
Exercise an Option 5 $396,045
Funding Only Action 4 $135,126
Funding Only Action 3 $223,364
Funding Only Action 2 $113,636
Funding Only Action 1 · Early therapeutics development with phase II emphasis -$350,246
Original award $629,300
Show all 19

About this award

Written by GovTribe AI ·

This is a federal contract award from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. (Moffitt Cancer Center) located in Tampa, Florida. The contract, valued at $15,602,467.00, is focused on early therapeutic development with an emphasis on Phase II clinical trials. The contract is not set aside for any specific business type. Moffitt Cancer Center, a nonprofit, NCI-designated comprehensive cancer center, has a history of federal contract and grant awards supporting a range of cancer research activities, including collaborations with other major cancer centers. This contract award likely supports Moffitt's expertise in areas such as cancer biology, bioinformatics, biostatistics, and clinical trials, which are critical to the NCI's cancer treatment research, cancer biology research, and cancer control programs.

Quick answers

Who was awarded contract HHSN261200622008C?

HHSN261200622008C was awarded to H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. by National Cancer Institute (National Institutes of Health) on January 1, 2006.

How much is contract HHSN261200622008C worth?

The government has obligated $3,953,085 on HHSN261200622008C. Its current value, with exercised options, is $12,405,967. Its potential value, with all options, is $15,602,467.

Was contract HHSN261200622008C competed?

The extent of competition for HHSN261200622008C was full and open competition. The government received 11 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login